Maravai LifeSciences Holdings, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Maravai supplies nucleic-acid products and biologics safety-testing products and services. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless noted.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $68.9 | $242.7 | $147.9 | $487.0 |
| Gross profit / margin | $25.6 / 37.2% | $205.2 / 84.6% | $71.0 / 48.0% | $409.5 / 84.1% |
| Operating income (loss) | $(11.6) | $180.7 | $(9.1) | $348.1 |
| Net income (loss) | $(11.9) | $156.7 | $(13.3) | $303.6 |
| Net income (loss) attributable to Maravai | $(6.5) | $71.2 | $(6.6) | $138.1 |
| Adjusted EBITDA (non-GAAP) | $9.1 | $188.5 | $32.9 | $375.5 |
| Adjusted free cash flow (non-GAAP) | $(18.0) | $178.5 | $4.6 | $362.8 |
Q2 revenue fell 71.6%; first-half revenue fell 69.6%. Nucleic Acid Production revenue declined 76.4% in Q2 and 74.4% in the first half. Biologics Safety Testing revenue declined 10.5% and 12.9%, respectively. Lower volume and a less favorable product mix, together with higher labor and facility costs and weaker manufacturing absorption, sharply compressed gross margins. Q2 diluted loss per Class A share was $0.05; first-half diluted loss was also $0.05 per share.
For the first half, operating cash flow was $104.3 million, down from $326.6 million. The 2023 figure benefited substantially from a $90.0 million decrease in accounts receivable; net loss replaced prior-year net income as the starting point. Investing cash outflow was $93.9 million, including $69.6 million net cash paid for Alphazyme and $32.9 million of property and equipment purchases, partly offset by $8.7 million of government funding. Financing cash outflow was $62.3 million, including tax-receivable-agreement (TRA) payments, tax distributions, debt repayments and an acquisition holdback payment.
At June 30, cash and cash equivalents were $580.2 million, versus $632.1 million at year-end 2022. Long-term debt had $535.8 million principal outstanding ($525.8 million carrying value net of issuance costs); the $180 million revolving facility had no borrowings. The term loan rate was 8.03%, and a $500 million interest-rate cap runs through January 2025. The company reported covenant compliance and a first-lien net leverage ratio below 4.25:1. Total liabilities included a $677.4 million TRA obligation. Management said available cash, operating cash generation and credit access should meet requirements over the next 12 months and beyond.
Material changes and management commentary
- Management attributed the sharp revenue decline principally to lower COVID-19 vaccine-related demand for CleanCap products. COVID-related products and services were estimated at 16.8% of Q2 revenue and 18.6% of first-half revenue, versus 73.2% and 71.8% in the comparable 2022 periods.
- CleanCap revenue was $27.3 million in Q2, of which an estimated $11.6 million related to COVID-19 demand; in Q2 2022, $190.6 million of CleanCap revenue included an estimated $177.6 million related to COVID-19 demand.
- Biologics Safety Testing was also pressured by slower biologics manufacturing, especially in Asia Pacific and EMEA. Management cited weaker early-stage biotech funding, customer spending restraint and economic contraction in Asia, particularly China, as potential continuing headwinds.
- Alphazyme was acquired in January 2023 for $75.3 million total purchase consideration, including $5.3 million estimated contingent consideration. Its results are included from the acquisition date. The deal added $42.8 million of goodwill and $31.7 million of intangible assets; purchase-price allocation remained preliminary.
Outlook, risks and unusual items
- Management expected further COVID-19-related revenue declines in the remainder of 2023, citing lower market demand and customer inventory on hand. Longer-term COVID-related revenue was described as highly uncertain and expected to remain substantially below pandemic highs.
- No specific revenue or earnings guidance is provided in the supplied filing text. Full-year 2023 capital expenditures were projected at $55–$65 million, net of anticipated government funding, primarily for the San Diego Flanders facility.
- Alphazyme performance payments could total up to $75 million if revenue targets are met during 2023–2025; the filing also describes $9.3 million of employee retention payments subject to continued employment. A further $20 million MyChem retention payment is subject to continued employment. These amounts are not included in the contractual-obligations table.
- The TRA requires payments to former owners equal to 85% of specified realized or deemed tax benefits. The recorded liability was $677.4 million; estimated future payments could be accelerated or exceed realized benefits following a change of control, material breach or early termination.
- The BARDA agreement provides up to $38.8 million, or 50% of eligible facility construction and validation costs. Reimbursements are subject to audit and possible recapture; the agreement also includes conditional priority access and pricing obligations for a public-health emergency for ten years after project completion.
- Other material risks include reliance on a limited customer base, customer spending and funding conditions, supplier concentration, product quality and regulatory risks, variable-rate debt, and acquisition execution. The filing reports no legal proceeding believed likely to have a material adverse effect.
Important facts for investors to verify
- Whether the steep COVID-related demand decline and customer inventory levels continue to reduce CleanCap sales and cash generation.
- Revenue stabilization, margins and demand trends in both segments, including customer spending and activity in Asia and EMEA.
- Cash conversion: first-half operating cash flow relied heavily on receivables collection, while capital spending and acquisition outlays remained substantial.
- Debt-rate exposure, the term-loan maturity concentration in 2027, covenant headroom, and the cost and timing of TRA obligations.
- Alphazyme integration, preliminary valuation assumptions, contingent-payment outcomes and retention commitments.
- Reconcile TRA payment disclosures: the cash-flow statement reports $42.2 million paid in the first half, while the related-party note describes $42.6 million.